An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors

An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07359066 by Shanghai SciBrunch Therapeutics Co., Ltd., with 210 participants planned, started 2026-01-08 and due to reach its primary completion in 2028-02. Interventions recorded: SRP1020.